— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected. — Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion. — For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is […]
“— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected. — Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion. — For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is […]
· January 30, 2020
— Alexion Pharmaceuticals,
Inc. (NASDAQ: ALXN) reported earnings
of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected.
— Total revenue
rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose
11% to $3.94 billion.
— For FY20,
Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is projected to
be $10.65 to $10.85.
— ALXN stock
gained 1.8% during pre-market hours immediately following the announcement.
Get access to timely and accurate
verbatim transcripts that are published within hours of the event.
